Klin Farmakol Farm. 2010;24(3):138-140 [Onkologie. 2010:4(2):106-109]
Faslodex 500 and new treatment options
- Masarykův onkologický ústav, Brno
One of the principal therapeutic procedures in metastatic breast cancer is hormonal therapy. In patients with positive oestrogen receptors,
it should be considered as first-line therapy, particularly due to its efficacy and good tolerability. Visceral metastases should not be a criterion
in favour of chemotherapy over hormonal therapy. Since they are well tolerated, aromatase inhibitors are recommended as first-line
hormonal therapy in postmenopausal patients. However, tamoxifen remains an acceptable option. The results of the recent CONFIRM and
FIRST clinical trials support the use of 500 mg fulvestrant every four weeks in patients in whom prior hormonal therapy failed.
Keywords: hormonal therapy, metastatic breast cancer, fulvestrant 500 mg
Published: October 15, 2010 Show citation
References
- Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance. Epidemiology, and End Resultes database: Breast Cancer Res Treat 2002; 76: 27-36.
Go to original source... 
Go to PubMed... - Hankey BF, Miller B, Curtis R, et al. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr 1994; 16: 7-14.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. Go to original source... Go to PubMed...
- Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects od chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-years survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717. Go to original source... Go to PubMed...
- Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozol for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combine analysis of two muilticentric trials. Cancer 2003; 98: 229-238. Go to original source... Go to PubMed...
- Kuter I, Hegg R, Singer CF, et al. Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast CancerRes Treat 2007; 106: 7(abstr 589).
- Robertson J, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 versus anastrozol 1 mg as first-line treatment for advanced breast cancer: resultes from the FIRST study. J Clin Oncol 2009; 27: 4530-4535. Go to original source... Go to PubMed...
- Di Leo A, Jerusalem G, Petruzelka L, et al. CONFIRM: a phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Program and abstracts of the 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, Texas. Abstract 25. Go to original source...
- Mauriac L, Piplej JE, Quaresma Albano J, et al. Fulvestrant (Faslodex) versus anastrozol for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases combined resultes from two multicentric trials. Eur J Cancer 2003; 39: 1228-1233. Go to original source... Go to PubMed...
- National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology-http://www.nccn.org/professional/physician.
- Beslija S, Bonneterre H, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2008; 18: 215-225. Go to original source... Go to PubMed...
- Boneneterre J, Thurlimann B, Robertson JF, et al. Anastrozol versus tamoxifen in first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757. Go to original source... Go to PubMed...
- Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozol is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767. Go to original source... Go to PubMed...
- Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. J Clin Oncol 2004; 22: 1605-1613. Go to original source... Go to PubMed...